Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan

Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational... Oncol Ther (2018) 6:203–215 https://doi.org/10.1007/s40487-018-0064-8 ORIGINAL RESEARCH Real-World EGFR T790M Testing in Advanced Non- Small-Cell Lung Cancer: A Prospective Observational Study in Japan . . . Takashi Seto Naoyuki Nogami Nobuyuki Yamamoto . . . . Shinji Atagi Naoki Tashiro Yoko Yoshimura Yutaka Yabuki Hideo Saka Received: July 3, 2018 / Published online: August 28, 2018 The Author(s) 2018 advanced/metastatic NSCLC who reported dis- ABSTRACT ease progression during treatment with first- or second-generation EGFR TKIs. Data regarding Introduction: Approximately one-half of sampling methods for T790M mutation testing patients with epidermal growth factor receptor (plasma sample, cytology or tissue biopsy) and (EGFR) mutation-positive advanced/metastatic the treatment strategies after disease progres- non-small-cell lung cancer (NSCLC) develop sion were recorded prospectively. resistance to first- or second-generation EGFR Results: A total of 236 patients were included tyrosine kinase inhibitors (TKIs) due to a sec- in the study (female, 67.4%; median age, ondary T790M mutation. This study investi- 73.0 years), and 205 patients (86.9%) under- gated the pattern of T790M testing after EGFR went rebiopsy by any of the three possible TKI treatment in a real-world setting in Japan. methods: plasma sampling in 137 patients Method: This prospective observational study (58.1%) and tissue/cytology sampling http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan

Download PDF
13 pages

Loading next page...
 
/lp/springer-journals/real-world-egfr-t790m-testing-in-advanced-non-small-cell-lung-cancer-a-IcG010cRE0
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-018-0064-8
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2018) 6:203–215 https://doi.org/10.1007/s40487-018-0064-8 ORIGINAL RESEARCH Real-World EGFR T790M Testing in Advanced Non- Small-Cell Lung Cancer: A Prospective Observational Study in Japan . . . Takashi Seto Naoyuki Nogami Nobuyuki Yamamoto . . . . Shinji Atagi Naoki Tashiro Yoko Yoshimura Yutaka Yabuki Hideo Saka Received: July 3, 2018 / Published online: August 28, 2018 The Author(s) 2018 advanced/metastatic NSCLC who reported dis- ABSTRACT ease progression during treatment with first- or second-generation EGFR TKIs. Data regarding Introduction: Approximately one-half of sampling methods for T790M mutation testing patients with epidermal growth factor receptor (plasma sample, cytology or tissue biopsy) and (EGFR) mutation-positive advanced/metastatic the treatment strategies after disease progres- non-small-cell lung cancer (NSCLC) develop sion were recorded prospectively. resistance to first- or second-generation EGFR Results: A total of 236 patients were included tyrosine kinase inhibitors (TKIs) due to a sec- in the study (female, 67.4%; median age, ondary T790M mutation. This study investi- 73.0 years), and 205 patients (86.9%) under- gated the pattern of T790M testing after EGFR went rebiopsy by any of the three possible TKI treatment in a real-world setting in Japan. methods: plasma sampling in 137 patients Method: This prospective observational study (58.1%) and tissue/cytology sampling

Journal

Oncology and Therapy – Springer Journals

Published: Aug 28, 2018

References

  • What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?
    Pirker, R
  • American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non–small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy
    Keedy, VL; Temin, S; Somerfield, MR
  • A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER)
    Shi, Y; Au, JS-K; Thongprasert, S
  • Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR
    Maemondo, M; Inoue, A; Kobayashi, K
  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
    Mitsudomi, T; Morita, S; Yatabe, Y
  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
    Zhou, C; Wu, Y-L; Chen, G
  • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    Rosell, R; Carcereny, E; Gervais, R
  • Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
    Sequist, LV; Yang, JC; Yamamoto, N
  • Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
    Wu, YL; Zhou, C; Hu, CP
  • New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
    Oxnard, GR; Arcila, ME; Chmielecki, J; Ladanyi, M; Miller, VA; Pao, W
  • Analysis of mechanisms of acquired resistance to EGFR TKI therapy in 155 patients with EGFR-mutant lung cancers
    Yu, H; Arcila, ME; Rekhtman, N
  • Acquired resistance to TKIs in solid tumours: learning from lung cancer
    Camidge, DR; Pao, W; Sequist, LV
  • EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Nan, X; Xie, C; Yu, X; Liu, J
  • Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC
    Walter, AO; Sjin, RTT; Haringsma, HJ
  • Third generation EGFR TKIs: current data and future directions
    Tan, CS; Kumarakulasinghe, NB; Huang, YQ
  • AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
    Cross, DA; Ashton, SE; Ghiorghiu, S
  • Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
    Goss, G; Tsai, C-M; Shepherd, FA
  • Osimertinib in pretreated T790M-positive advanced non–small-cell lung cancer: AURA study phase II extension component
    Yang, JCH; Ahn, MJ; Kim, DW
  • Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer
    Mok, TS; Wu, Y-L; Ahn, M-J
  • Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
    Soria, J-C; Ohe, Y; Vansteenkiste, J
  • Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development
    Yver, A
  • Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure
    Kawamura, T; Kenmotsu, H; Taira, T
  • Re-biopsy status among non-small cell lung cancer patients in Japan: a retrospective study
    Nosaki, K; Satouchi, M; Kurata, T
  • Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer
    Li, X; Zhou, C
  • Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
    Lin, CC; Shih, JY; Yu, CJ
  • Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp
    Nagai, Y; Miyazawa, H; Tanaka, T
  • A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer
    Yatabe, Y; Hida, T; Horio, Y; Kosaka, T; Takahashi, T; Mitsudomi, T
  • Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay
    Arcila, ME; Oxnard, GR; Nafa, K
  • Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
    Sequist, LV; Waltman, BA; Dias-Santagata, D
  • Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
    Kuiper, J; Heideman, D; Thunnissen, E
  • The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?
    Kwapisz, D
  • Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer
    Oxnard, GR; Thress, KS; Alden, RS
  • EGFR mutation analysis for prospective patient selection in two phase II registration studies of osimertinib
    Jenkins, S; Chih-Hsin Yang, J; Janne, PA
  • Association of EGFR exon 19 deletion and EGFR-TKI treatment duration with frequency of T790M mutation in EGFR-mutant lung cancer patients
    Matsuo, N; Azuma, K; Sakai, K
  • Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update
    Hanna, N; Johnson, D; Temin, S